Rheumatoid Arthritis Increases Risk of Lower GI Events

Article

Though researchers continue to investigate exactly why, data indicates RA increases an individual's risk of lower GI bleeding or perforation, diverticulitis, lower GI ulcers, and appendicitis.

This Mayo Clinic poster session was quite popular with attendees, who likely took interest because lower GI complications in RA are much less studied than upper GI events, of which there is strong evidence in RA patients.

Researchers examined two cohorts—RA and non-RA—of a patient population based in Olmsted County, Minnesota, all of whom were first diagnosed between 1980 and 1998.

“We analyzed incidence data from medical records and found that lower GI events are more likely to occur in patients with RA,” says Dr. Elena Mayasoedova of the Mayo Clinic. “These events include lower GI bleeding or perforation, diverticulitis, lower GI ulcers, and appendicitis.”

Data indicated that RA patients are also at an increased risk for surgical interventions (especially for bowel obstructions) and hospitalizations (diverticular disease, GI bleeding or perforation, and infectious colitis,) for lower GI events.

Despite these findings, the fact that researchers conducted an observational study prevented them from drawing hard conclusions about pathogenesis, but do suspect that RA severity and medications are viable culprits.

Mayasoedova does caution that most patients in this study were diagnosed before the introduction and widespread use of biologics, and because follow up was ongoing for 14 years, it is possible that biologics were introduced into therapy at some point. “For this reason we couldn’t exclude the impact of biologics and seek to further analyze the correlation between drugs, medications, and incidents of lower GI in our further studies.”

Recent Videos
Arshad Khanani, MD: Four-Year Outcomes of Faricimab for DME in RHONE-X | Image Credit: Sierra Eye Associates
Dilraj Grewal, MD: Development of MNV in Eyes with Geographic Atrophy in GATHER | Image Credit: Duke Eye Center
Margaret Chang, MD: Two-Year Outcomes of the PDS for Diabetic Retinopathy | Image Credit: Retina Consultants Medical Group
Carl C. Awh, MD: | Image Credit:
Raj K. Maturi, MD: 4D-150 for nAMD in PRISM Population Extension Cohort | Image Credit: Retina Partners Midwest
Charles C. Wykoff, MD, PhD: Interim Analysis on Ixo-Vec Gene Therapy for nAMD | Image Credit: Retina Consultants of Texas
Sunir J. Garg, MD: Pegcetacoplan Preserves Visual Function on Microperimetry | Image Credit: Wills Eye Hospital
Edward H. Wood, MD: Pharmacodynamics of Subretinal RGX-314 for Wet AMD | Image Credit: Austin Retina Associates
Dilsher Dhoot, MD: OTX-TKI for NPDR in Interim Phase 1 HELIOS Results  | Image Credit: LinkedIn
Katherine Talcott, MD: Baseline EZ Integrity Features Predict GA Progression | Image Credit: LinkedIn
© 2024 MJH Life Sciences

All rights reserved.